1-855-378-42281-855-378-4228
One of the out-patient treatment options for individuals in Trimble struggling with opioid dependence and addiction is opioid maintenance therapy. Licensed clinics and doctors are authorized to give specific medications to opioid dependent individuals, many of which are opioid-based themselves and are addiction. With low amounts however, the individual does not feel high but also doesn't have acute cravings and isn't experiencing opioid withdrawal. Methadone is the first drug tried for this reason, but there are a few more choices currently to select from.
Methadone is an opioid and can be taken at an out-patient medical center licensed to administer the med, which is taken daily as a pill or liquid. The price of the med is about $150 per month. Buprenorphine is also an opioid-based drug, and is in pill form often taken one day on, one day off. But different from Methadone that can only be dispensed in well-regulated medical centers, Buprenorphine can be prescribed and administered in doctor's offices. The monthly cost of buprenorphine is around three hundred dollars monthly for the generic version of the medication. There is also a type of buprenorphine containing the drug naloxone, which is a drug that reverses the effects of opioids. An individual taking this formulation, AKA Suboxone, would find it more difficult to get high from opioids if they relapsed while taking the drug. It too is taken every day, and is priced approximately $450 /month. Naltrexone is an additional medication used in opioid maintenance therapy, but unlike the other medications aforementioned it is an opioid blocker and isn't an opiate. A person has the choice to take this medication as a monthly injection, and that is called Vivitrol. As an opioid blocker, the drug prevents an individual from experience being high from opioids, and therefore lowers the risk associated with relapse. This daily shot costs anywhere from $1000 to $1200 monthly.
For All Alcohol and Drug Treatment Facilities In Trimble, Click Here.
